Outcome probabilities (with 95% confidence interval) stratified by conditioning intensity and pre- and/or post-HCT MRD status
| . | Cumulative incidence of relapse at 3 y . | RFS at 3 y . | OS at 3 y . | Cumulative incidence of NRM at 100 d . | Cumulative incidence of NRM at 3 y . |
|---|---|---|---|---|---|
| All patients (n = 810) | 32% (28-35%) | 54% (50-57%) | 60% (56-63%) | 3% (2-4%) | 15% (12-17%) |
| Pre-HCT MRD information only | |||||
| MRDneg (n = 649) | 23% (20-27%) | 62% (58-65%) | 66% (62-70%) | 4% (3-6%) | 15% (12-18%) |
| MRDpos (n = 161) | 65% (57-72%) | 21% (15-28%) | 33% (26-41%) | 6% (3-10%) | 15% (10-21%) |
| Post-HCT MRD information only | |||||
| MRDneg (n = 749) | 27% (24-30%) | 58% (54-61%) | 64% (60-67%) | 5% (4-7%) | 15% (13-18%) |
| MRDpos (n = 61) | 90% (78-96%) | 2% (0-8%) | 13% (6-23%) | 0% (—) | 8% (3-18%) |
| Peri-HCT MRD information | |||||
| MRDneg/MRDneg (n = 631) | 21% (18-24%) | 63% (60-67%) | 68% (64-72%) | 4% (3-6%) | 15% (13-18%) |
| MRDneg/MRDpos (n = 18) | 100% (—) | 0% (—) | 6% (0-22%) | 0% (—) | 0% (—) |
| MRDpos/MRDneg (n = 118) | 57% (47-65%) | 28% (20-36%) | 40% (30-49%) | 8% (4-13%) | 15% (10-23%) |
| MRDpos/MRDpos (n = 43) | 86% (72-94%) | 2% (0-11%) | 16% (7-29%) | 0% (—) | 12% (4-24%) |
| MRDdecreasing (n = 143) | 62% (53-69%) | 24% (17-31%) | 36% (28-45%) | 6% (3-11%) | 15% (10-21%) |
| MRDstable/increasing (n = 36) | 100% (—) | 0% (—) | 6% (1-16%) | 0% (—) | 0% (—) |
| MAC HCT (n = 515) | 28% (24-32%) | 61% (57-65%) | 66% (61-70%) | 5% (3-7%) | 11% (8-14%) |
| Pre-HCT MRD information only | |||||
| MRDneg (n = 411) | 19% (15-23%) | 71% (66-75%) | 74% (70-78%) | 4% (2-6%) | 10% (7-13%) |
| MRDpos (n = 104) | 66% (56-74%) | 21% (13-29%) | 33% (24-42%) | 7% (3-13%) | 14% (8-21%) |
| Post-HCT MRD information only | |||||
| MRDneg (n = 493) | 25% (22-29%) | 64% (59-68%) | 68% (63-72%) | 5% (3-7%) | 11% (9-14%) |
| MRDpos (n = 22) | 91% (61-98%) | 5% (0-19%) | 18% (6-36%) | 0% (—) | 5% (0-20%) |
| Peri-HCT MRD information | |||||
| MRDneg/MRDneg (n = 408) | 18% (14-22%) | 72% (67-76%) | 75% (70-79%) | 4% (2-7%) | 10% (8-14%) |
| MRDneg/MRDpos (n = 3) | 100% (—) | 0% (—) | 0% (—) | 0% (—) | 0% (—) |
| MRDpos/MRDneg (n = 85) | 61% (49-70%) | 24% (15-34%) | 35% (25-46%) | 0% (—) | 15% (9-24%) |
| MRDpos/MRDpos (n = 19) | 90% (56-98%) | 5% (0-21%) | 21% (7-41%) | 0% (—) | 5% (0-23%) |
| MRDdecreasing (n = 99) | 64% (54-73%) | 22% (14-30%) | 33% (25-44%) | 7% (3-13%) | 14% (8-22%) |
| MRDstable/increasing (n = 8) | 100% (—) | 0% (—) | 0% (—) | 0% (—) | 0% (—) |
| Non-MAC HCT(n = 295) | 37% (32-43%) | 41% (35-46%) | 49% (43-55%) | 5% (3-8%) | 22% (17-27%) |
| Pre-HCT MRD information only | |||||
| MRDneg (n = 238) | 31% (26-37%) | 45% (39-52%) | 53% (46-59%) | 5% (3-8%) | 32% (18-29%) |
| MRDpos (n = 57) | 62% (48-74%) | 21% (11-33%) | 33% (21-46%) | 4% (1-11%) | 17% (9-28%) |
| Post-HCT MRD information only | |||||
| MRDneg (n = 256) | 29% (24-35%) | 47% (41-53%) | 55% (49-61%) | 6% (3-9%) | 24% (19-29%) |
| MRDpos (n = 39) | 100% (—) | 0% (—) | 10% (3-22%) | 0% (—) | 8% (2-20%) |
| Peri-HCT MRD information | |||||
| MRDneg/MRDneg (n = 223) | 27% (21-33%) | 49% (42-55%) | 56% (49-62%) | 5% (3-9%) | 25% (19-31%) |
| MRDneg/MRDpos (n = 15) | 100% (—) | 0% (—) | 7% (0-26%) | 0% (—) | 0% (—) |
| MRDpos/MRDneg (n = 33) | 46% (28-62%) | 39% (22-55%) | 50% (31-66%) | 6% (1-18%) | 16% (6-31%) |
| MRDpos/MRDpos (n = 24) | 100% (—) | 0% (—) | 13% (3-29%) | 0% (—) | 9% (1-33%) |
| MRDdecreasing (n = 44) | 55% (39-69%) | 27% (15-42%) | 40% (25-55%) | 5% (1-14%) | 25% (19-31%) |
| MRDstable/increasing (n = 28) | 100% (—) | 0% (—) | 7% (1-20%) | 0% (—) | 7% (1-24%) |
| . | Cumulative incidence of relapse at 3 y . | RFS at 3 y . | OS at 3 y . | Cumulative incidence of NRM at 100 d . | Cumulative incidence of NRM at 3 y . |
|---|---|---|---|---|---|
| All patients (n = 810) | 32% (28-35%) | 54% (50-57%) | 60% (56-63%) | 3% (2-4%) | 15% (12-17%) |
| Pre-HCT MRD information only | |||||
| MRDneg (n = 649) | 23% (20-27%) | 62% (58-65%) | 66% (62-70%) | 4% (3-6%) | 15% (12-18%) |
| MRDpos (n = 161) | 65% (57-72%) | 21% (15-28%) | 33% (26-41%) | 6% (3-10%) | 15% (10-21%) |
| Post-HCT MRD information only | |||||
| MRDneg (n = 749) | 27% (24-30%) | 58% (54-61%) | 64% (60-67%) | 5% (4-7%) | 15% (13-18%) |
| MRDpos (n = 61) | 90% (78-96%) | 2% (0-8%) | 13% (6-23%) | 0% (—) | 8% (3-18%) |
| Peri-HCT MRD information | |||||
| MRDneg/MRDneg (n = 631) | 21% (18-24%) | 63% (60-67%) | 68% (64-72%) | 4% (3-6%) | 15% (13-18%) |
| MRDneg/MRDpos (n = 18) | 100% (—) | 0% (—) | 6% (0-22%) | 0% (—) | 0% (—) |
| MRDpos/MRDneg (n = 118) | 57% (47-65%) | 28% (20-36%) | 40% (30-49%) | 8% (4-13%) | 15% (10-23%) |
| MRDpos/MRDpos (n = 43) | 86% (72-94%) | 2% (0-11%) | 16% (7-29%) | 0% (—) | 12% (4-24%) |
| MRDdecreasing (n = 143) | 62% (53-69%) | 24% (17-31%) | 36% (28-45%) | 6% (3-11%) | 15% (10-21%) |
| MRDstable/increasing (n = 36) | 100% (—) | 0% (—) | 6% (1-16%) | 0% (—) | 0% (—) |
| MAC HCT (n = 515) | 28% (24-32%) | 61% (57-65%) | 66% (61-70%) | 5% (3-7%) | 11% (8-14%) |
| Pre-HCT MRD information only | |||||
| MRDneg (n = 411) | 19% (15-23%) | 71% (66-75%) | 74% (70-78%) | 4% (2-6%) | 10% (7-13%) |
| MRDpos (n = 104) | 66% (56-74%) | 21% (13-29%) | 33% (24-42%) | 7% (3-13%) | 14% (8-21%) |
| Post-HCT MRD information only | |||||
| MRDneg (n = 493) | 25% (22-29%) | 64% (59-68%) | 68% (63-72%) | 5% (3-7%) | 11% (9-14%) |
| MRDpos (n = 22) | 91% (61-98%) | 5% (0-19%) | 18% (6-36%) | 0% (—) | 5% (0-20%) |
| Peri-HCT MRD information | |||||
| MRDneg/MRDneg (n = 408) | 18% (14-22%) | 72% (67-76%) | 75% (70-79%) | 4% (2-7%) | 10% (8-14%) |
| MRDneg/MRDpos (n = 3) | 100% (—) | 0% (—) | 0% (—) | 0% (—) | 0% (—) |
| MRDpos/MRDneg (n = 85) | 61% (49-70%) | 24% (15-34%) | 35% (25-46%) | 0% (—) | 15% (9-24%) |
| MRDpos/MRDpos (n = 19) | 90% (56-98%) | 5% (0-21%) | 21% (7-41%) | 0% (—) | 5% (0-23%) |
| MRDdecreasing (n = 99) | 64% (54-73%) | 22% (14-30%) | 33% (25-44%) | 7% (3-13%) | 14% (8-22%) |
| MRDstable/increasing (n = 8) | 100% (—) | 0% (—) | 0% (—) | 0% (—) | 0% (—) |
| Non-MAC HCT(n = 295) | 37% (32-43%) | 41% (35-46%) | 49% (43-55%) | 5% (3-8%) | 22% (17-27%) |
| Pre-HCT MRD information only | |||||
| MRDneg (n = 238) | 31% (26-37%) | 45% (39-52%) | 53% (46-59%) | 5% (3-8%) | 32% (18-29%) |
| MRDpos (n = 57) | 62% (48-74%) | 21% (11-33%) | 33% (21-46%) | 4% (1-11%) | 17% (9-28%) |
| Post-HCT MRD information only | |||||
| MRDneg (n = 256) | 29% (24-35%) | 47% (41-53%) | 55% (49-61%) | 6% (3-9%) | 24% (19-29%) |
| MRDpos (n = 39) | 100% (—) | 0% (—) | 10% (3-22%) | 0% (—) | 8% (2-20%) |
| Peri-HCT MRD information | |||||
| MRDneg/MRDneg (n = 223) | 27% (21-33%) | 49% (42-55%) | 56% (49-62%) | 5% (3-9%) | 25% (19-31%) |
| MRDneg/MRDpos (n = 15) | 100% (—) | 0% (—) | 7% (0-26%) | 0% (—) | 0% (—) |
| MRDpos/MRDneg (n = 33) | 46% (28-62%) | 39% (22-55%) | 50% (31-66%) | 6% (1-18%) | 16% (6-31%) |
| MRDpos/MRDpos (n = 24) | 100% (—) | 0% (—) | 13% (3-29%) | 0% (—) | 9% (1-33%) |
| MRDdecreasing (n = 44) | 55% (39-69%) | 27% (15-42%) | 40% (25-55%) | 5% (1-14%) | 25% (19-31%) |
| MRDstable/increasing (n = 28) | 100% (—) | 0% (—) | 7% (1-20%) | 0% (—) | 7% (1-24%) |